Table 3

Multivariate adjusted relative risk (95% confidence interval (CI)) and area under the receiver operating characteristic curve in men

Multivariate adjusted relative risk (95% CI)
StudyAUCAgeSBPSerum TCSmokingDM
The multivariate adjusted relative risks and the 95% CIs were estimated using a proportional hazards models with age, SBP, serum TC, current smoking, and DM status included as independent variables in the models. Relative risks associated with specified increments of the characteristics were calculated based on this multivariate model. The increments used were 10 years of age, 20 mm Hg SBP, 1.04 mmol/l TC, current smoking versus current non-smoker, and DM versus non-DM.
NHANES I732.19 (1.98 to 2.42)1.28 (1.20 to 1.38)1.11 (1.04 to 1.18)1.33 (1.11 to 1.59)2.17 (1.60 to 2.94)
NHANES II782.84 (2.39 to 3.37)1.28 (1.16 to 1.43)1.12 (1.01 to 1.25)2.03 (1.57 to 2.64)1.73 (1.15 to 2.60)
Framingham cohort802.12 (1.81 to 2.48)1.34 (1.17 to 1.53)1.22 (1.07 to 1.40)1.37 (1.03 to 1.82)1.99 (1.23 to 3.21)
Tecumseh community health study812.48 (2.10 to 2.94)1.46 (1.28 to 1.67)1.32 (1.14 to 1.53)1.86 (1.32 to 2.63)1.85 (0.94 to 3.66)
Honolulu heart program802.12 (1.73 to 2.60)1.59 (1.45 to 1.75)1.39 (1.25 to 1.55)2.02 (1.61 to 2.55)2.85 (2.17 to 3.75)
Puerto Rico heart health program
    Urban762.01 (1.63 to 2.49)1.56 (1.43 to 1.70)1.27 (1.16 to 1.40)1.43 (1.10 to 1.87)2.88 (2.07 to 4.03)
    Rural772.23 (1.56 to 3.19)1.66 (1.43 to 1.94)1.15 (0.95 to 1.41)1.44 (0.92 to 2.25)2.86 (1.23 to 6.60)
Yugoslavia cardiovascular disease study
    Urban822.11 (1.64 to 2.71)1.56 (1.35 to 1.80)1.33 (1.16 to 1.52)1.54 (1.03 to 2.30)4.63 (2.15 to 9.96)
    Rural822.20 (1.58 to 3.06)1.81 (1.49 to 2.20)0.86 (0.67 to 1.10)2.05 (1.13 to 3.71)
Scottish collaborative study752.03 (1.77 to 2.32)1.45 (1.34 to 1.56)1.28 (1.19 to 1.38)1.90 (1.61 to 2.25)1.65 (0.78 to 3.51)
Renfrew and Paisley study682.13 (1.90 to 2.40)1.31 (1.24 to 1.37)1.18 (1.11 to 1.26)1.58 (1.39 to 1.79)2.73 (1.93 to 3.87)
Glostrup cohort772.09 (1.67 to 2.61)1.53 (1.28 to 1.83)1.20 (1.05 to 1.38)2.09 (1.38 to 3.16)2.52 (1.26 to 5.02)
Norwegian counties study732.25 (1.88 to 2.69)1.54 (1.43 to 1.65)1.29 (1.24 to 1.34)2.55 (2.18 to 2.98)3.98 (2.62 to 6.03)
Iceland Reykjavik study752.36 (2.13 to 2.61)1.40 (1.31 to 1.50)1.34 (1.25 to 1.44)1.75 (1.49 to 2.05)1.78 (1.17 to 2.71)
Israeli ischemic heart disease study792.08 (1.88 to 2.31)1.51 (1.43 to 1.60)1.33 (1.24 to 1.42)1.56 (1.35 to 1.79)2.31 (1.86 to 2.87)
Lipid research clinics follow-up study
    Random sample832.50 (1.92 to 3.26)1.40 (1.13 to 1.72)1.40 (1.10 to 1.77)1.91 (1.18 to 3.09)8.05 (3.80 to 17.03)
    Hyperlipidaemic792.39 (1.85 to 3.09)1.17 (0.92 to 1.50)1.27 (1.16 to 1.39)1.82 (1.11 to 2.99)3.79 (1.60 to 8.98)
HDFP (regular care)731.95 (1.56 to 2.44)1.31 (1.13 to 1.52)1.12 (0.99 to 1.25)1.60 (1.14 to 2.25)1.79 (1.06 to 3.05)
MRFIT (usual care)661.74 (1.37 to 2.20)1.41 (1.19 to 1.66)1.22 (1.06 to 1.41)2.02 (1.51 to 2.71)1.24 (0.61 to 2.51)